TAXOL® (paclitaxel) 1-hour infusion plus doxorubicin as first line treatment for metastatic breast cancer (MBC) patients
E. Mickiewicz(University of Chicago), A.M. Alvarez, G Uranga, G Temperley, S. Grasso(Instituto Oncológico de Córdoba), M. Rondinón, María Eva Vallejo Pascual, M. Ventnglia, Eduardo Cazap(Facultad Latinoamericana de Ciencias Argentina), Gonzalo Rubio, S Jovtis, Roberto Estevez, Masahiro Noto, S. Breier, Daniel Lewi, Mariana Trigo, Carlos Bas, Ayelén Bertoncin
Cited by 0
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318
LEVAMISOLE IN ADVANCED HUMAN BREAST CANCER
|The Lancet|1976|159